提供: Vaccipedia | Resources for Vaccines, Tropical medicine and Travel medicine
ナビゲーションに移動
検索に移動
Navigation Menu
|
|
General issues of Vaccine
|
|
General issues of Tropical med.
|
|
General issues of Travel med.
|
|
Trematode (fluke, distoma)
|
|
epidemiology
- 1.19mi. deaths in 2016
- 197.05 mil. episodes in 2016
- the leading cause of lower respiratory infections followed by H. influenzae, influenza /B and RS virus
- 50% of pneumococcal deaths in India, Nigeria, DRC and Pakistan
serotype
- all serotypes known more than 90 are pathogenic for human
- differentiation of serotypes is important for epidemiology
antimicrobial resitance
- first reported in late 1960s
Vaccine
- PPSV does not induce T-cell dependent immunity
- PCV induces T-cell dependent immunity
- new product "Pneumosil" from India
- 10-valent
- serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
- the reason why PCV13 for older population failed to show persistent efficacy against IPD in the U.S. may be contributed by spread of PCV13 for children which has caused serotype substitutions in community
History of Pneumococcal vaccines in Japan
|
Brand name
|
Approval for children
|
Introduction to childhood routine immunization
|
Approval for adults
|
Introduction to adult routine immunization
|
Note
|
PPSV23
|
ニューモバックスNP Pneumovax NP
|
1988(昭和63年) ≥ 2 y/o
|
N/A†
|
1988(昭和63年)
|
2014(平成26年) only for all 65 y/o or 60-64 with specific conditions†
|
PCV7
|
プレベナー Prevenar
|
2009(平成21年)
|
2010(平成22年)
|
N/A
|
M/A
|
Sales terminated and switched to PCV13 in 2013
|
PCV13
|
プレベナー13 Prevenar 13
|
2013(平成25年)
|
2013(平成25年)
|
2014(平成26年)≥ 65 y/o
2020(平成28年) people at high risk of IPD irrespective of age
|
N/A
|
|
PCV15
|
バクニュバンス Vaxneuvance
|
2023(令和5年)
|
N/A as of 2023
|
2022(令和4年) people at high risk of IPD irrespective of age
|
N/A
|
PCV20
|
|
Under review as of 2023
|
|
|
|
|
†covered by Public Health Insurance for asplenia
*Table updated on 24th Aug 2023
Serotype replacement
Overwhelming Post-Splenectomy Infection (OPSI) and pnuemococcus